Latest Content

Pulmonary rehabilitation boosts respiratory strength, the 6-minute walking test, and quality of life in children despite unchanged spirometry.

Men with multiple sclerosis (MS) were more likely to lose income earlier in life compared with women with MS.

DELTA 2 data show topical delgocitinib for chronic hand eczema delivers minimal systemic absorption even under maximal-use conditions.

Teclistamab bispecific from Johnson & Johnson boosts early-line multiple myeloma outcomes, fueling safer outpatient therapy options.

Twice-yearly depemokimab reduced exacerbations and improved quality-of-life outcomes in type 2 asthma and CRSwNP studies.

Resmetirom boosts MASH cardiovascular protection, lowering LDL cholesterol and Lp(a) even on statins, and pushes routine Lp(a) testing.

Systematic review finds SGLT2 inhibitors and newer CKD drugs boost QALYs and often save costs by delaying dialysis and transplant.

New data showed durable hepatitis D virus RNA suppression through 96 weeks with tobevibart plus elebsiran, while higher BMI appeared to affect ALT normalization.

Reports highlight gaps in private equity oversight, MA vs FFS outcomes, cancer care access advances, climate health disparities, and uneven genomic testing.